Bayesian Network Meta-Analysis of Targeted Therapies for Advanced Thyroid Cancer

A Bayesian network meta-analysis of 9 randomized controlled trials involving 1,760 patients with metastatic or advanced radioiodine-refractory differentiated thyroid cancer. The analysis, published by Pin Wang on figshare, compares the efficacy and safety of targeted therapies, with primary outcomes including progression-free survival and objective response rate. The dataset was last updated in March 2026.

Use Cases

• Compare the progression-free survival benefit of different tyrosine kinase inhibitors based on hazard ratios.
• Rank treatments for safety based on the analysis of grade ≥3 adverse events.
• Evaluate the time-dependent efficacy patterns of therapies like apatinib based on the described waning benefit.
• Assess the objective response rate of treatments like lenvatinib based on the reported odds ratios.

Strengths

• Analysis is based on 9 randomized controlled trials, a standard for clinical evidence.
• Includes data from 1,760 patients, providing a substantial sample for meta-analysis.
• Uses Bayesian network meta-analysis, a sophisticated statistical method for comparing multiple treatments.
• Reports specific statistical results, such as hazard ratios and SUCRA ranking scores.

Limitations

• Dataset is a 17.4 KB DOCX file, suggesting limited raw data and likely a summary document.
• Row count and column-level documentation are unknown, limiting suitability assessment for direct data analysis.
• The data is derived from a systematic review; its freshness depends on the included trial publication dates.

Provenance

Source

Systematic search of six electronic databases, as described in the methods.

Collection Method

Bayesian network meta-analysis of randomized controlled trials.

Freshness

Last updated 2026-03-18 07:35:12; freshness should be verified against more recent clinical trials.